Pharmaceutical Commerce - February 2022

Click the title above for a link to open the Pharmaceutical Commerce February 2022 issue in an interactive PDF format.

Introducing our first deep dive into pharma's indispensable partner—the 3PL

Today’s ideal pharma third-party logistics (3PL) provider brings the right mix of physical assets, internal expertise, data analytics and strategic partnerships to function as a seamless extension of a manufacturer’s internal operations—no matter what disruptions arise

The growing complexity and demand in distribution amid the pandemic present unique technology opportunities for third-party logistics providers

A conversation with Michael Abrams, co-founder and managing partner, Numerof & Associates

As more of these novel—and costly—cell therapies gain approval, revamped strategies around scaling, coordination and workflow are critical to their launch

Examining the divestment risks, as more large companies look to spin off consumer health and other business units to focus on branded pharmaceuticals

Can technology really build trust in pharmaceutical supply chains?

With the delivery of Covid-19 booster shots in full swing, how does this effort compare to the initial vaccine distribution—and is the pharma supply chain adapting accordingly?

The benefits of hybrid direct-to-patient studies and supply chain structures in boosting drug access, influencing clinical trial design